Bicyclerd Limited

Boehringer Ingelheim International Gmbh

Tmem16a Limited

Boehringer Ingelheim Pharma Gmbh & Co Kg

Bicycletx Limited

Bicycle Therapeutics Limited

Edward Walker

Catherine Lucy Stace

Daniel Paul Teufel

John Tite

Silvia Pavan

Georg Dahmann

Matthias Hoffmann

Clive Mccarthy

Leonardo Baldassarre

Jasna Klicic

Duncan Alexander Hay

Jonathan David Hargrave

Stephen Collingwood

Guenter Linz

Gerhard Schaenzle

Andreas Schnapp

Sandra Handschuh

Dennis Fiegen

John Scott

Thomas Beauregard Schofield

Christopher Charles Stimson

Michael Philip Mazanetz

Spencer Charles R Napier

Peter Neville Ingram

David James Lamb

Robert John Scott

Sarah Ellam

Chun Yan Ma

Craig Stephen Buxton

Matthew Habgood

Abdul Kadar Shaikh

Matthew Raymond Smith

Jennifer L Swantek Fitzgerald

Spencer Charles Robert Napier

Karen Parrish

Liuhong Chen

Stephen East

Punit Upadhyaya

Christian Heinis

Stephen Peter East

Jasna Klicic Badoux

Leonardo Baldassare

Stephen P East

Catherine Stace

Spencer Napier

Compounds of general formula (I): wherein R, R, R, R, A, Z, Zand Y are as defined herein are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A.

Modulators of TMEM16A for treating respiratory disease

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of prostrate-specific membrane antigen (PSMA). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PSMA.

Bicyclic peptide ligands specific for PSMA

Compounds of general formula (I): wherein R, R, R, R, R, RX, X, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.

Compounds

The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP), such as the collagen binding site of MT1-MMP. The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups which have utility in imaging and targeted cancer therapy.

Bicyclic peptide ligands specific for MT1-MMP

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP). The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups which have utility in imaging and targeted cancer therapy.

The invention describes peptide ligands specific for human plasma Kallikrein.

Modulation of structured polypeptide specificity

Compounds of general formula (I): wherein R, R, R, R, R, R* X, X, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions. 

The invention relates to new substituted heteroaryls of formula 1 wherein

Heteroaryl SYK inhibitors

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are specific for the human and rat protease plasma kallikrein and are modified in one or two peptide loops to enhance potency and/or protease resistance.

Polypeptide ligands specific for plasma kallikrein

Growing community of inventors

Cambridge, United Kingdom

Edward Walker